de Vries, F.

Profileringshoogleraar, Hospital Pharmacist

View graph of relations
  1. Article › Academic › Peer-reviewed
  2. Published
    Hjellvik, V., De Bruin, M. L., Samuelsen, S. O., Karlstad, Ø., Andersen, M., Haukka, J., ... Furu, K. (2019). Adjusting for unmeasured confounding using validation data: Simplified two-stage calibration for survival and dichotomous outcomes. Statistics in Medicine, 38(15), 2719-2734.
  3. Published
  4. Published
  5. Published
  6. Published
  7. Published
  8. Published
    de Groot, M. C. H., Schuerch, M., de Vries, F., Hesse, U., Oliva, B., Gil, M., ... Klungel, O. H. (2014). Antiepileptic drug use in seven electronic health record databases in Europe: A methodologic comparison. Epilepsia, 55(5), 666-673.
  9. Published
    Klop, C., Gibson-Smith, D., Elders, P. J. M., Welsing, P. M. J., Leufkens, H. G. M., Harvey, N. C., ... de Vries, F. (2015). Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000-2010. Osteoporosis International, 26(7), 1919-1928.
  10. Published
  11. Published
  12. Published
  13. Published
  14. Published
  15. Published
    Lalmohamed, A., Welsing, P. M. J., Lems, W. F., Jacobs, J. W. G., Kanis, J. A., Johansson, H., ... De Vries, F. (2012). Calibration of FRAX (R) 3.1 to the Dutch population with data on the epidemiology of hip fractures. Osteoporosis International, 23(3), 861-869.
  16. Published
  17. Published
    But, A., De Bruin, M. L., Bazelier, M. T., Hjellvik, V., Andersen, M., Auvinen, A., ... Haukka, J. (2017). Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study. Diabetologia, 60(9), 1691-1703.
  18. Published
  19. Published
  20. Published
  21. Published
    Klop, C., de Vries, F., Lalmohamed, A., Mastbergen, S. C., Leufkens, H. G. M., Noort-van der Laan, W. H., ... Welsing, P. M. J. (2012). COX-2-Selective NSAIDs and Risk of Hip or Knee Replacements: A Population-Based Case-Control Study. Calcified Tissue International, 91(6), 387-394.
  22. Published
  23. Published
  24. Published
  25. Published
  26. Published
  27. Published
  28. Published
  29. Published
  30. Published
  31. Published
  32. Published
  33. Published
  34. Published
  35. Published
  36. Published
  37. Published
  38. Published
  39. Published
  40. Published
  41. Published
  42. Published
  43. Published
  44. Published
    Requena, G., Abbing-Karahagopian, V., Huerta, C., de Bruin, M. L., Alvarez, Y., Miret, M., ... de Abajo, F. J. (2014). Incidence Rates and Trends of Hip/Femur Fractures in Five European Countries: Comparison Using E-Healthcare Records Databases. Calcified Tissue International, 94(6), 580-589.
  45. Published
  46. Published
  47. Published
  48. Published
  49. Published
    Peeters, P. J. H. L., Bazelier, M. T., Leufkens, H. G. M., Auvinen, A., van Staa, T. P., de Vries, F., & De Bruin, M. L. (2016). Insulin glargine use and breast cancer risk: Associations with cumulative exposure. Acta Oncologica, 55(7), 851-858.
  50. Published
    Klop, C., Welsing, P. M. J., Elders, P. J. M., Overbeek, J. A., Souverein, P. C., Burden, A. M., ... de Vries, F. (2015). Long-term persistence with anti-osteoporosis drugs after fracture. Osteoporosis International, 26(6), 1831-1840.
  51. Published
Previous 1 2 3 Next